PolyHeme

Overview
PolyHeme is a temporary oxygen-carrying blood substitute made from human hemoglobin that is currently in development for emergency treatment of trauma situations where large volumes of blood are lost, with emphasis on situations where fresh blood for transfusion is not readily available. It originally began as a military project following the Vietnam war and is currently being developed by Northfield Laboratories, Inc.

Production
PolyHeme is a solution of human hemoglobin extracted from red blood cells that has been modified using a multi-step polymerization process. The purified hemoglobin is associated into tetramers and is incorporated into an electrolyte solution. The polymerization of the hemoglobin represents the critical advance in the development of artificial blood. Previous attempts using non-polymerized hemoglobin caused vasoconstriction. Also, filtration of free globin chains by the kidney causes renal failure. The company currently uses expired human blood from which the hemoglobin is extracted and purified. The hemoglobin molecule is the pyridoxylated to raise the P50. Subsequently, this hemoglobin is polymerized with glutaraldehyde.

Benefits
PolyHeme is universally compatible with all blood types and so it doesn't require cross-matching or typing prior to infusion. In any tests completed to date, there have been no recorded transfusion reactions and it is manufactured from human red blood cells and has gone through steps to reduce the risk of viral infection. It has a shelf life of over twelve months. PolyHeme can be stored at room temperature, versus donated whole blood which requires refrigeration. This makes PolyHeme advantageous in emergency situations. Another advantage is its acceptance by patients seeking bloodless medical care. It does not have most attributes of whole blood, such as the ability to coagulate.

Development and production
On May 23, 2006, Northfield Labs selected Jacobs Engineering Group Inc. to provide engineering services for a new biological manufacturing facility. The facility will consist of commercial manufacturing space in a facility adjacent to Northfield Laboratories' existing pilot plant operations in Mt. Prospect, Ill and will include production modules, laboratories, warehousing, utility support, and offices.

Additionally, on June 16, 2006, Northfield Labs announced that it had signed an agreement to purchase a 106,000 square foot property that it had been leasing to be used as the first planned commercial facility to manufacture PolyHeme. The Mt. Prospect, IL facility was purchased for $6.7 millions and is expected to be capable of producing at least 100,000 units of PolyHeme annually.

Clinical trials and consent controversy
Polyheme finished a Phase III trauma trial in June 2006.

The testing was completed at more than 25 Level I trauma centers in the United States under a Food and Drug Administration special category (21CFR 50.24) in 1996 that allows its use without patient consent in special circumstances. PolyHeme was the 15th such experiment allowed by the FDA. Although Northfield Laboratories came under scrutiny for this trial, enrollment of the 720 patient trial was completed on July 31, 2006.

The controversy arose from the fact that the participants in this study were incapable of giving their consent due to the nature of their injuries. The only way to opt out from the study was by wearing a special bracelet prior to needing emergency care (the bracelet can be requested by calling 717-531-5829). Even though this practice is sanctioned by the FDA as necessary emergency research, patients’ rights groups protested the study.

Lists of the participating hospitals can be found at and.

Petition for fast track
In a financial analysts and investors meeting on August 8, 2006 in New York, Northfield Labs revealed that it had just sent in an application to the FDA for Fast Track designation of PolyHeme and that by law, the FDA was supposed to provide a response within two months. If a Fast Track designation is approved, Northfield planned to request for Priority Review when it submit its Biologic License Application (BLA) sometime in the first half of the year 2007. Fast Track is a feature of the FDA Modernization Act of 1997 and is intended to facilitate the development and expedite the review of products intended for the treatment of serious or life-threatening conditions and which demonstrate the potential to address an unmet medical need for such a condition. It was also re-stated that the company expected to report top-line results of PolyHeme's Phase III study in the fall of 2006.

In a press release on October 10, 2006, it was released that Northfield Labs and the FDA had both agreed to defer the Fast Track designation until the availability of the top-line result in the fall. Fast Track designation was deferred because the FDA needs to know not just the product, but also the indication for which the product will be used. The indication was yet to be determined because the PolyHeme Phase III trial had two primary endpoints of superiority and non-inferiority. And until the release of the top-line result, whether either, both or none of the endpoints were met is unknown.

The Phase III trial was designed as an "active-control dual superiority-noninferiority trial comparing the survival of PolyHeme patients to those who received standard treatment (salt water plus blood)". On December 19, 2006, Northfield Labs released preliminary results of the trial, and the mortality data was disappointing: 13.2 percent of patients receiving PolyHeme died versus 9.6 percent among the control group. This news led to Northfield shares plummeting more than 50%. However, the company remains optimistic, noting that of the 712 randomized treatment patients, 20% of the PolyHeme group and 15% of the control group were protocol violations, leaving a valid total of 586 patients. Northfield is currently re-evaluating the study database to determine if any additional statistical errors are present. They expect to announce any release of the final results only after error corrections are complete. Additional safety data is also expected from the CRO in four to six weeks from the December 19 announcement.